From the practical wisdom of emphasising exercise to improve survival in colon cancer to the association of glucagon-like ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

EY's latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts ...

Small transactions may not always make the headlines, but they’re the lifeblood of pharma innovation. So says Juergen ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

A smartphone app developed by Otsuka and digital health firm Click Therapeutics has been launched in Great Britain – its ...

NHS cost-effectiveness overseer NICE has published new guidance recommending IL-36 inhibitor Spevigo (spesolimab) for the ...

Published in the Journal of the American Medical Association (JAMA), the letter says that the dismissal of the advisors and ...

The PMS requirement applies to all UKCA- and CE-marked devices, like in vitro diagnostics (IVDs), glucose monitors, and ...

The financing has been billed as the most significant commercial investment into Welsh research to date, and will help Draig ...

FDA Commissioner Marty Makary has revealed a new priority review voucher programme for new medicines deemed to be of national ...